Form 4: Foghorn Therapeutics Inc. Executive Anna Rivkin Reports Stock Option Grant
SEC Form 4 Filing
Anna Rivkin, Chief Business Officer of Foghorn Therapeutics Inc., reports the acquisition of stock options.
Summary
- Anna Rivkin, Chief Business Officer of Foghorn Therapeutics Inc. (FHTX), filed a Form 4 on September 4, 2024, reporting a transaction.
- On September 3, 2024, Rivkin acquired 190,000 stock options with an exercise price of $7.85.
- These options vest as to 25% on September 3, 2025, and then at a rate of 6.25% per quarter until fully vested.
- Following the transaction, Rivkin directly owns 190,000 derivative securities.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management with shareholder interests.
Positives
- The grant of stock options to the Chief Business Officer aligns her interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- The vesting schedule of 25% after one year followed by quarterly vesting is a typical arrangement.
- Comparing the size of the grant to similar companies and executive roles would provide further context.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Business Officer to drive company growth.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of stock option grant and transaction. |
| 09/03/2025 | First vesting date for 25% of the stock options. |
| 09/04/2024 | Date of Form 4 filing. |
| 09/03/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.